Roche’s Actemra Scores New Indication In Rare Autoimmune Disease
SSc-ILD Indication Comes With Biosimilar Competition On The Horizon
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
